



ECST-2 is an international randomised trial investigating the optimal treatment of patients with symptomatic or asymptomatic moderate or severe carotid stenosis at low or intermediate risk of future stroke. The trial compares the risks and benefits of treatment by modern optimised medical management alone versus the addition of immediate carotid surgery (or stenting) to optimised medical management.

News and updates:

Welcome to the March edition of the ECST2 newsletter.

We will be announcing the date of next year's investigators meeting soon, in the meantime if you are going to the European Stroke Conference in Nice why not come and visit us at the stand we will be sharing with ACST-2?

The following 7 centres have enrolled in ECST-2:

University College Hospital London, Sheffield Teaching Hospitals,
Cumberland Infirmary, Nottingham University Hospital,
Universitäts Klinikum Magdeburg Germany,
Leeds Teaching Hospitals and Calderdale & Huddersfield NHS Trust.

The following centres have randomised patients in ECST-2:

UCLH	38
Leeds Infirmary	2
Calderdale & Huddersfield NHS Trust	2

New centres are welcome to enrol in the trial – if you have any enquiries you can contact us using the details given at the bottom of this letter.

Reminder:

Patients should have a brain MRI at randomisation.

Reminder:

Remember to screen **all** carotid Stenosis patients for suitability to enrol in ECST-2 using our website.

The team:

Chief Investigator: Prof Martin M Brown
Clinical Research Fellow: Dr Fiona Kennedy
Trial Manager: Dr Roland L Featherstone
Trial Administrator: Ms Esther Davies

Contact:

Telephone: 02034483870. Fax: 02078379632 Website: www.ecst-2.com Email: office@ecst2.com